One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving ...

Combination treatment with a PARP inhibitor and an anti-angiogenic agent did not improve PFS when compared to chemotherapy or a PARP inhibitor alone.

Olaparib, which is taken as tablets, is already available on the NHS. A class of cancer drug known as a PARP inhibitor, it ...

A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers, according to Cambridge researchers.

Overall survival (OS) in BRCA -mutated breast cancer improved significantly with the addition of olaparib (Lynparza) to ...

Treating patients with a drug before surgery greatly reduced the chances of the cancer coming back, a small trial found.

A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers, ...

A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers, according to Cambridge ...

First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at ...

The firm will test LP-184 as a monotherapy and in combination with a PARP inhibitor in patients who have DNA damage repair gene mutations.